Mirae Asset Global Investments
ABUS icon

Mirae Asset Global Investments’s Arbutus Biopharma ABUS Stock Holding History

Mirae Asset Global Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.4K Sell
8,835
-1,197
-12% -$5.26K ﹤0.01% 1379
2026
Q1 		$45.1K Buy
10,032
+686
+7% +$3K ﹤0.01% 1315
2025
Q4 		$45K Buy
9,346
+1,935
+26% +$8.7K ﹤0.01% 1414
2025
Q3 		$33.6K Buy
7,411
+12
+0.2% +$44 ﹤0.01% 1411
2025
Q2 		$22.9K Buy
7,399
+1,058
+17% +$3.51K ﹤0.01% 1381
2025
Q1 		$22.2K Buy
6,341
+26
+0.4% +$87 ﹤0.01% 1382
2024
Q4 		$20.3K Sell
6,315
-513
-8% -$1.89K ﹤0.01% 1422
2024
Q3 		$26.2K Buy
6,828
+1,194
+21% +$4.58K ﹤0.01% 1397
2024
Q2 		$17.5K Buy
+5,634
New +$16.9K ﹤0.01% 1400

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
CCA
Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mirae Asset Global Investments's ABUS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Arbutus Biopharma (ABUS) stake by 12% in Q2 2026, selling an estimated $5.26K and leaving 8,835 shares worth $42.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

Mirae Asset Global Investments first reported a position in ABUS in Q2 2024 and has held it in 9 quarters since. The position peaked at $45.1K in Q1 2026. 51 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Mirae Asset Global Investments held 8,835 shares of Arbutus Biopharma worth $42.4K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,197 Arbutus Biopharma shares in Q2 2026, an estimated $5.26K.
  • Arbutus Biopharma made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1379 holding.
  • Mirae Asset Global Investments first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global Investments's Arbutus Biopharma position peaked at $45.1K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.